Treatment with corticosteroids of long-standing nerve function impairment in leprosy: A randomized controlled trial (TRIPOD 3)

Leprosy Review

Volumn 74, Issue 4, 2003, Pages 311-318

  Richardus, Jan H ^a   Withington, Stephen G ^b   Anderson, Alison M ^c   Croft, Richard P ^d   Nicholls, Peter G ^e   Van Brakel, Wim H ^f   Smith, W Cairns S ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Danish Bangladesh Leprosy Mission   (Bangladesh)

^c International Nepal Fellowship   (Nepal)

^d Polwarth Building ^*  (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CORTICOSTEROID; PLACEBO; PREDNISOLONE;

ACNE; ADOLESCENT; ADULT; ARTICLE; BANGLADESH; CATARACT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; GLAUCOMA; HUMAN; HYPERTENSION; LEPROSY; MAJOR CLINICAL STUDY; MOON FACE; MULTICENTER STUDY; MYCOSIS; NEPAL; NERVE FUNCTION; NERVE FUNCTION IMPAIRMENT; NEUROPATHY; PEPTIC ULCER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PAIN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPROSY; MALE; MIDDLE AGED; NEPAL; NEURAL CONDUCTION; ODDS RATIO; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDNISOLONE; PROBABILITY; RECOVERY OF FUNCTION; REFERENCE VALUES; RISK ASSESSMENT; SENSATION DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0346694425     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pearson JM. The use of corticosteroids in leprosy. Lepr Rev, 1981; 52: 293-298.
2. Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev, 1991; 62: 113-121.
3. Croft RP, Nicholls PG, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev, 2000; 71: 154-168.
4. Kiran KU, Stanley JN, Pearson JM. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Lepr Rev, 1985; 56: 127-134.
5. Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis, 1992; 60: 173-184.
6. Moet FJ, Rongong NT. Prednisolone treatment in longer standing sensation loss. Int J Lepr Other Mycobact Dis, 1993; 61: 19A.
7. Croft R, Richardus JH, Smith WC. The effectiveness of corticosteroids in the treatment of long-term nerve function impairment. Lepr Rev, 1996; 67: 342-343.
8. Richardus JH, Smith WCS. The risk of standardized regimens of corticosteroids for the treatment of leprosy reactions in the field. Lepr Rev, 1996; 67: 328-329.
9. Richardus JH, Withington SG, Anderson AM et al. Adverse events of standardised regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Lepr Rev, 2003; 74: 000-000.
10. Van Brakel WH, Anderson AM, Withington SG et al. Treatment of mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev, 2003; 74: 000-000.
11. Kets CM, Van Leerdam ME, Van Brakel WH et al. Reference values for touch sensibility thresholds in healthy Nepalese volunteers. Lepr Rev, 1996; 67: 28-38.
12. Brandsma W. Basic nerve function assessment in leprosy patients. Lepr Rev, 1981; 52: 161-170.
13. van Brakel WH, Anderson AM. Impairment and disability in leprosy: in search of the missing link. Ind J Lepr, 1997;69:361-376.
14. Saunderson P, Gebre S, Desta K et al. The pattern of leprosy related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev, 2000; 71: 285-308.